首页> 美国卫生研究院文献>Clinical and Experimental Immunology >Immunization of mice with baculovirus-derived recombinant SV40 large tumour antigen induces protective tumour immunity to a lethal challenge with SV40-transformed cells.
【2h】

Immunization of mice with baculovirus-derived recombinant SV40 large tumour antigen induces protective tumour immunity to a lethal challenge with SV40-transformed cells.

机译:用杆状病毒衍生的重组SV40大肿瘤抗原免疫小鼠可诱导保护性肿瘤免疫力抵抗SV40转化细胞的致死性攻击。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, we examined the humoral immune responses and in vivo tumour immunity induced by baculovirus recombinant simian virus 40 (SV40) large tumour antigen (rSV40 T-ag). BALB/c mice immunized with rSV40 T-ag produced antibody responses that recognized SV40 large tumour antigen (T-ag) by ELISA. Analysis of these anti-SV40 T-ag responses indicated that the antibodies recognized epitopes associated with both the carboxy and amino terminus of SV40 T-ag. This pattern of SV40 T-ag epitope recognition was similar to that observed in anti-SV40 T-ag responses induced by inoculation with irradiated SV40-transformed cells. Mice immunized with either rSV40 T-ag or with the inactivated transformed cells were protected from a subsequent in vivo lethal tumour challenge with live SV40-transformed cells. These studies suggest that humoral immune responses induced by rSV40 T-ag are similar in epitope specificity to that induced by inactivated SV40-transformed cells. In addition, recombinant tumour-specific antigens from papovaviruses, such as SV40, can be used to induce tumour immunity which protects from a subsequent lethal tumour challenge. This study may provide insight into the use of recombinant tumour antigens as putative tumour vaccines and in the development of active immunotherapeutic strategies for treating virus-induced cancers.
机译:在这项研究中,我们检查了由杆状病毒重组猿猴病毒40(SV40)大肿瘤抗原(rSV40 T-ag)诱导的体液免疫反应和体内肿瘤免疫。用rSV40 T-ag免疫的BALB / c小鼠产生的抗体反应通过ELISA识别了SV40大肿瘤抗原(T-ag)。对这些抗SV40 T-ag反应的分析表明,抗体识别与SV40 T-ag的羧基和氨基末端均相关的表位。 SV40 T-ag表位识别的这种模式类似于在接种经SV40转化的辐射细胞后诱导的抗SV40 T-ag反应中观察到的模式。用活SV40转化的细胞保护了用rSV40 T-ag或灭活的转化细胞免疫的小鼠免于随后的体内致死性肿瘤攻击。这些研究表明,rSV40 T-ag诱导的体液免疫应答的表位特异性与灭活的SV40转化细胞诱导的体液免疫应答相似。另外,来自乳头状病毒的重组肿瘤特异性抗原,例如SV40,可用于诱导肿瘤免疫,从而保护其免受随后的致死性肿瘤攻击。这项研究可能为深入了解重组肿瘤抗原作为推定的肿瘤疫苗的用途以及开发主动免疫疗法来治疗病毒诱导的癌症提供了见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号